The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)

被引:0
作者
Laura Iogna Prat
Emmanuel A. Tsochatzis
机构
[1] Royal Free Hospital and UCL,UCL Institute for Liver and Digestive Health
来源
Hormones | 2018年 / 17卷
关键词
Steatohepatitis; Metformin; Liraglutide; Pioglitazone; HCC;
D O I
暂无
中图分类号
学科分类号
摘要
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and is prevalent in more than 50% of patients with type II diabetes. At present, there is no approved therapy for NASH. Until now, the only proven effective interventions in improving biochemical and histological features of NASH, including fibrosis, are weight loss and physical activity even without weight loss. Because of the common epidemiological and pathophysiological features between NAFLD and T2DM, many antidiabetics drugs have been tested in patients with NAFLD over the years. Among these, pioglitazone and liraglutide seem to improve some histological features of NASH but have no clear effect on fibrosis. Metformin has been largely studied in the past years without convincing evidence of improving NAFLD. Data on other compounds such as DDP-4 and SGLT-2 inhibitors are limited. The rational and results of such studies are discussed in the present review.
引用
收藏
页码:219 / 229
页数:10
相关论文
共 347 条
[71]  
Niemeier HM(2016)Glycemic control and weight outcomes for Exenatide once weekly versus Liraglutide in patients with type 2 diabetes: a 1-year retrospective cohort analysis Clin Ther 38 2642-415
[72]  
Glass LM(2013)Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program Aliment Pharmacol Ther 37 234-1346
[73]  
Dickson RC(2017)Effect of Liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study J Clin Endocrinol Metab 102 407-2593
[74]  
Anderson JC(2015)Effects of insulin glargine and Liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial Diabetes Care 38 1339-408
[75]  
Vilar-Gomez E(2016)Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial Diabetologia 59 2588-2315
[76]  
Martinez-Perez Y(2016)Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis J Hepatol 64 399-529
[77]  
Calzadilla-Bertot L(2011)Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes Obesity (Silver Spring) 19 2310-891
[78]  
Houghton D(2014)Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes Diabetes Metab Res Rev 30 521-2709
[79]  
Thoma C(2016)Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy Diabetes Obes Metab 18 882-1211
[80]  
Hallsworth K(2010)Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series Am J Gastroenterol 105 2707-242